Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Down 7.9 %

Shares of TRVN stock opened at $1.28 on Thursday. Trevena has a 12-month low of $1.13 and a 12-month high of $12.25. The firm has a fifty day moving average of $1.62 and a 200-day moving average of $2.14. The company has a market capitalization of $1.11 million, a price-to-earnings ratio of -0.03 and a beta of 1.05.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.